A review of some recently published scientific studies includes one for antihistamines and similar compounds that might slow down Huntington’s disease.

A Phase III trial is planned after promising results were revealed from Dana-Farber Cancer Institute for MK-6482 in advanced clear cell kidney cancer.

First-time marathon runners can add years to their lives and reap the health rewards of lower blood pressure and healthier arteries, even if they take on the challenge in mid-to-later life, research showed.

The U.S. Food and Drug Administration approved Alexion Pharmaceuticals Inc.’s Ultomiris for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy for adult and pediatric patients.

Novartis received approval from the U.S. Food and Drug Administration for the Swiss pharmaceuticals company’s drug Beovu to treat a cause of vision loss.

The FDA approved Gadavist for use in cardiac magnetic resonance imaging to assess myocardial perfusion and late gadolinium enhancement in adults with known or suspected CAD.

A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease – via an eye test.

Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.

Novartis announced that the U.S. Food and Drug Administration granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises in patients of all genotypes with sickle cell disease.

The U.S. Food and Drug Administration approved Eli Lilly and Co.’s migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.